EU regulator assesses risk of thrombosis due to AstraZeneca vaccine
The benefits of Vaxzevria outweigh the risks for adults of all age groups – – The EMA recommends continuing to use AstraZeneca vaccine as a second dose 4 to 12 weeks after the first dose. The European Medicines Agency (EMA) has clarified the data on the risk of thrombosis when vaccinated with the coronavirus drug … Read more